Eli Lil­ly, Glax­o­SmithK­line-Vir re­lease pos­i­tive but dif­fi­cult-to-in­ter­pret com­bo an­ti­body da­ta

As vari­ants threat­ened Eli Lil­ly’s so­lo Covid-19 an­ti­body bam­lanivimab, the com­pa­ny teamed with ri­vals on a po­ten­tial com­bo ap­proach. Now they’ve de­clared in­ter­im suc­cess, though it’s not clear whether the re­sults sup­port the com­bo or just show how good their ri­val’s is alone.

The In­di­anapo­lis phar­ma on Mon­day an­nounced that a com­bi­na­tion of bam­lanivimab and the Glax­o­SmithK­line-Vir an­ti­body VIR-7831 suc­cess­ful­ly re­duced vi­ral loads in a Phase II study. Low-risk pa­tients who re­ceived the drug af­ter di­ag­no­sis saw a 70% greater re­duc­tion in virus af­ter 7 days than pa­tients on place­bo. There were al­so sta­tis­ti­cal­ly sig­nif­i­cant vi­ral re­duc­tions af­ter days 3 and 5.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.